Survival of
            <i>Lactobacillus reuteri</i>
            DSM 17938 and
            <i>Lactobacillus rhamnosus</i>
            GG in the Human Gastrointestinal Tract with Daily Consumption of a Low-Fat Probiotic Spread

Dommels, Yvonne E.M.; Kemperman, Robèr; Zebregs, Yvonne E. M. P.; Draaisma, René B.; Jol, Arne; Wolvers, Danielle; Vaughan, Elaine E.; Albers, Ruud

doi:10.1128/aem.01054-09

Cited by 71 publications

(62 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…L. casei DN-114 001 cells have been found in ileal and fecal samples of human volunteers receiving fermented milk containing L. casei DN-114 001 or the derived L. casei strain DN-114 001Rif (279,280). In human adult volunteers and infants, L. reuteri ATCC 55730 cells have been found in fecal samples (275,281,282). It is noteworthy that probiotic Lactobacillus strains do not colonize the gut and that the persistence of a strain is limited to the duration of the administration of the probiotic preparation.…”

Section: Clinical Studiesmentioning

confidence: 92%

“…For example, in conventional or germfree mice, L. rhamnosus GG cells have been found in the different segments of the gut (130), and L. johnsonii NCC 553 and L. casei Shirota cells efficiently colonize the different parts of the conventional mouse intestine (128). In human adults and infants receiving L. rhamnosus GG, the strain has been found in fecal and/or intestinal mucosa biopsy samples (270)(271)(272)(273)(274)(275). L. casei Shirota cells have been found in the feces of human volunteers receiving fermented milk containing L. casei .…”

Section: Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Infective Activities of Lactobacillus Strains in the Human Intestinal Microbiota: from Probiotics to Gastrointestinal Anti-Infectious Biotherapeutic Agents

2014

View full text Add to dashboard Cite

SUMMARY A vast and diverse array of microbial species displaying great phylogenic, genomic, and metabolic diversity have colonized the gastrointestinal tract. Resident microbes play a beneficial role by regulating the intestinal immune system, stimulating the maturation of host tissues, and playing a variety of roles in nutrition and in host resistance to gastric and enteric bacterial pathogens. The mechanisms by which the resident microbial species combat gastrointestinal pathogens are complex and include competitive metabolic interactions and the production of antimicrobial molecules. The human intestinal microbiota is a source from which Lactobacillus probiotic strains have often been isolated. Only six probiotic Lactobacillus strains isolated from human intestinal microbiota, i.e., L. rhamnosus GG, L. casei Shirota YIT9029, L. casei DN-114 001, L. johnsonii NCC 533, L. acidophilus LB, and L. reuteri DSM 17938, have been well characterized with regard to their potential antimicrobial effects against the major gastric and enteric bacterial pathogens and rotavirus. In this review, we describe the current knowledge concerning the experimental antibacterial activities, including antibiotic-like and cell-regulating activities, and therapeutic effects demonstrated in well-conducted, placebo-controlled, randomized clinical trials of these probiotic Lactobacillus strains. What is known about the antimicrobial activities supported by the molecules secreted by such probiotic Lactobacillus strains suggests that they constitute a promising new source for the development of innovative anti-infectious agents that act luminally and intracellularly in the gastrointestinal tract.

show abstract

Section: Clinical Studiesmentioning

confidence: 92%

Section: Clinical Studiesmentioning

confidence: 99%

Anti-Infective Activities of Lactobacillus Strains in the Human Intestinal Microbiota: from Probiotics to Gastrointestinal Anti-Infectious Biotherapeutic Agents

2014

View full text Add to dashboard Cite

show abstract

“…Finally, pure bacterial culture was tested for genetic identity using PCR with genus specific primers, as below. Lactobacillus reuteri PCR was performed according to the L-reu-1 and L-reu-4 primers (Integrated Data Technologies) described by Dommels et al [33]. L-reu-1: 5'-CAG ACA ATC TTT GAT TGT TTA -3' and L-REU-4: 5'-GTC TGT TGG TTT GGG CTC TTC -3' with Amplification of Initial denaturation 95 degrees Celsius for 5 minutes and then 35 cycles of Denaturing: 95 degrees Celsius for 1 minute, Annealing: 60 degrees Celsius for 1 minute, and Extension: 72 degrees Celsius for 1 minute.…”

Section: Isolation Characterization and Confirmation Of L Reuteri 2546mentioning

confidence: 99%

Beneficial Dog Bacteria Up-Regulate Oxytocin and Lower Risk of Obesity

Varian¹,

Levkovich²,

Poutahidis³

et al. 2017

J Prob Health

View full text Add to dashboard Cite

AnimalsC57BL/6 wild type (wt), oxytocin-wt (oxt-wt) and oxytocin- AbstractCohabitation with pet dogs imparts diverse health benefits to humans including a slim physique. It is known that neuropeptide hormone oxytocin fundamental in human-canine social bonds regulates appetite and body weight. It was recently shown in mice that consuming Lactobacillus reuteri ATCC 6475 from human breast milk lowers body weight and up-regulates oxytocin levels in blood. Here we test the hypothesis that bacteria from dog saliva may similarly modulate recipient host body weight. We find that a Lactobacillus spp isolate from dog saliva led to lower body weight when fed to C57BL/6 wild type mice. Mice consuming the canineborne L. reuteri also had elevated oxytocin levels in blood plasma, and exhibited body weight in an oxytocin-dependent manner. Interestingly, killed (lysed) canine bacteria were sufficient to achieve the physiological effects. Taken together, these studies provide evidence that dog bacteria modulate oxytocin levels and body weight in recipient mice, and thus may help reduce risk of obesity in individuals cohabitating with pet dogs. knockout (oxt-ko) B6; 129S-Oxttm1Wsy/J mice (purchased initially from Jackson labs; Bar Harbor, ME) were used in three separate experiments (Figure 1). Mice were housed and handled in Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facilities using techniques and diets including Lactobacillus reuteri as specifically approved by Massachusetts Institute of Technology's (MIT) Committee on Animal Care (CAC). Mice were housed under standard 12:12 light cycle conditions with lights on at 7 AM. Mice were fed a standard control chow Purina RMH3000. Beneficial Dog Bacteria Up-Regulate Oxytocin and Lower Risk of ObesityMice were bred in-house to achieve experimental groups. Each experiment included 5-15 animals per group with one or two replications (total N=10-30 mice examined per group) unless otherwise specified. For the initial studies, C57BL/6 wt mice received Lactobacillus reuteri 2546 isolated from dog saliva. To test putative roles for microbeinduced oxytocin in obesity, oxt-ko mice and their oxt-wt littermates entered experiments at eight weeks of age. At the conclusion of the study mice were euthanized with CO 2 overdose, and were examined as described below. Eight pet dogs served as saliva microbe donors as approved by the MIT-CAC. Saliva was collected from these dogs in the morning before feeding using sterile swabs [Puritan Sterile Polyester Tipped applicators Guilford, Me Ref: 25-806 1PD] in 1.5 ml centrifuge tubes (Safeseal Microcentrifuge Tubes, Sorenson Bioscience Inc. Salt Lace City, UT Cat# 16070). Bacteria were purified from dog saliva as described in detail below. PCR of dog saliva for all Lactobacillus speciesSaliva was collected from eight pet dogs and prepared using High Pure PCR Template kit (Roche Diagnostics) was used without changes to the manufacturer's directions to isolate DNA from the canine saliva. DNA was measured using Nan...

show abstract

“…This may answer the question: Are these bacteria suitable as an effective chemopreventive agent against CRC development, since they have the same survival as other bacteria for 4 h in SIF? Furthermore, even after 24 h, they are still viable at log 6, which strongly suggests they are viable in the intestinal environment [48].…”

Section: Citationmentioning

confidence: 96%

Screening and In-Vitro Analysis of Lactobacillus reuteri Strains for Short Chain Fatty Acids Production, Stability and Therapeutic Potentials in Colorectal Cancer

M¹

2015

J Bioequiv Availab

View full text Add to dashboard Cite

Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the Human Gastrointestinal Tract with Daily Consumption of a Low-Fat Probiotic Spread

Cited by 71 publications

References 35 publications

Anti-Infective Activities of Lactobacillus Strains in the Human Intestinal Microbiota: from Probiotics to Gastrointestinal Anti-Infectious Biotherapeutic Agents

Anti-Infective Activities of Lactobacillus Strains in the Human Intestinal Microbiota: from Probiotics to Gastrointestinal Anti-Infectious Biotherapeutic Agents

Beneficial Dog Bacteria Up-Regulate Oxytocin and Lower Risk of Obesity

Screening and In-Vitro Analysis of Lactobacillus reuteri Strains for Short Chain Fatty Acids Production, Stability and Therapeutic Potentials in Colorectal Cancer

Contact Info

Product

Resources

About